Mink Therapeutics Inc

MiNK Therapeutics is a clinical-stage biopharmaceutical company developing unmodified, off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapies and precision-targeted immune technologies for cancer, immune-mediated diseases and pulmonary immune failure.

Its lead candidate, agenT-797, is a cryopreserved iNKT cell therapy delivered from inventory without apheresis, HLA matching or lymphodepletion. It is being studied in several settings:
- A randomized, placebo-controlled Phase 2 trial in acute respiratory distress syndrome (C-1300-02).
- An investigator-sponsored Phase 2 study with botensilimab/balstilimab in MSS colorectal cancer with liver metastases at Scripps.
- A Phase 1 GvHD prevention study at the University of Wisconsin–Madison.
- A pediatric blood cancer program (C-Further).

agenT-797 is also supplied on a paid, per-patient basis through an international named-patient access program, which generated the company's initial pre-commercial product revenue in Q3 2026.

The pipeline also includes MiNK-215, an FAP-targeted, IL-15-armored CAR-iNKT candidate with preclinical activity against senescent cells and fibroblasts relevant to cancer and fibrotic lung disease. MiNK is the selected cell therapy for a Draper-led team in ARPA-H's BioStabilization Systems program, which aims to enable room-temperature deployment of living medicines. The company relies on non-dilutive partners to advance platform programs while concentrating internal spending on the ARDS trial. Updated Nov 12, 2026